APICHOPE PHARMACEUTICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.61 CNY | -2.04% |
|
-4.36% | -24.20% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,339 | 10,200 | 9,894 | 13,394 | 10,153 | - | - |
| Enterprise Value (EV) 1 | 6,339 | 10,200 | 9,894 | 13,394 | 10,153 | 10,153 | 10,153 |
| P/E ratio | 28.1 x | 33.6 x | 36.2 x | 71 x | 41.1 x | 21.9 x | 26.5 x |
| Yield | - | - | 0.58% | 0.7% | 0.44% | 0.57% | - |
| Capitalization / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 3.56 x | 2.6 x | 2.62 x |
| EV / Revenue | 3.78 x | - | 4.34 x | 5.35 x | 3.56 x | 2.6 x | 2.62 x |
| EV / EBITDA | - | - | 26.7 x | 34.4 x | 16.6 x | 13.5 x | 13.7 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | 5.12 x | 5.37 x | 3.8 x | 3.19 x | 3.19 x |
| Nbr of stocks (in thousands) | 425,993 | 426,174 | 429,162 | 449,027 | 449,027 | - | - |
| Reference price 2 | 14.88 | 23.93 | 23.05 | 29.83 | 22.61 | 22.61 | 22.61 |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,675 | - | 2,280 | 2,503 | 2,851 | 3,902 | 3,868 |
| EBITDA 1 | - | - | 369.9 | 389.8 | 612.8 | 752.6 | 739.5 |
| EBIT 1 | - | - | 282 | 213.9 | 271 | 518.9 | 433.1 |
| Operating Margin | - | - | 12.37% | 8.55% | 9.51% | 13.3% | 11.2% |
| Earnings before Tax (EBT) 1 | - | - | 326.4 | 244.2 | 307.8 | 544.1 | 461.9 |
| Net income 1 | - | 306.9 | 290.7 | 184.6 | 250.3 | 463.7 | 386.8 |
| Net margin | - | - | 12.75% | 7.37% | 8.78% | 11.88% | 10% |
| EPS 2 | 0.5296 | 0.7133 | 0.6373 | 0.4200 | 0.5500 | 1.032 | 0.8533 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.1333 | 0.2100 | 0.1000 | 0.1300 | - |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 14.6% | 8.14% | 8.76% | 14% | 11.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | 6.2% | 8.67% | 8.1% |
| Assets 1 | - | - | - | - | 4,038 | 5,351 | 4,775 |
| Book Value Per Share 2 | - | - | 4.500 | 5.550 | 5.940 | 7.080 | 7.080 |
| Cash Flow per Share 2 | - | - | 1.100 | 1.010 | 1.370 | 1.620 | 1.530 |
| Capex 1 | - | - | 606 | 334 | 313 | 244 | 374 |
| Capex / Sales | - | - | 26.56% | 13.36% | 10.97% | 6.24% | 9.68% |
| Announcement Date | 3/29/21 | 4/20/22 | 4/19/23 | 4/26/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
22.61
CNY
Average target price
30.31
CNY
Spread / Average Target
+34.06%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.20% | 1.41B | |
| +21.28% | 43.92B | |
| +24.47% | 23.09B | |
| +19.22% | 15.35B | |
| +12.87% | 13.61B | |
| +44.67% | 12.02B | |
| -9.92% | 7B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.07% | 5.6B |
- Stock Market
- Equities
- 300723 Stock
- Financials ApicHope Pharmaceutical Co., Ltd